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OBJECTIVES We investigated the efficacy of percutaneous coronary intervention (PCI) in patients with
coronary spastic angina (CSA) and severe organic stenosis.
BACKGROUND Coronary spasm occurs at the site of organic stenosis in most patients with CSA and severe
stenosis, whereas multivessel spasm occurs frequently in those with normal coronary arteries.
The incidence of multivessel spasm and the efficacy of PCI in patients with CSA and severe
stenosis have not been fully elucidated.
METHODS Forty-five patients with CSA and severe stenosis underwent spasm provocative testing with
intracoronary acetylcholine before and 7  3 months after PCI (20 patients had angioplasty
and 25 patients had stenting), when all patients were free of restenosis.
RESULTS Spasm was induced at the site of severe stenosis in 30 patients (66.7%) with (n  12) or
without (n  18) spasm induced in another vessel. In the remaining 15 patients, spasm was
induced at a different site in the stenotic vessel and/or in another vessel. Repeat provocative
tests were performed in 43 of 45 patients. Although spasm was never induced at exactly the
same site of the initial stenosis that had been dilated, spasm was induced at a different site in
the dilated vessel and/or in another vessel, in 33 (76.7%) of 43 patients. Multivessel spasm
occurred in 28 (62.2%) of 45 patients on one or both provocations.
CONCLUSIONS Spasm was frequently induced at a site different from the initial stenosis, even in the absence
of restenosis after PCI. Calcium antagonists should be continued in most patients with CSA
who show no restenosis after PCI. (J Am Coll Cardiol 2002;39:1120–6) © 2002 by the
American College of Cardiology Foundation
The coronary anatomy in patients with coronary spastic
angina (CSA) is variable, from angiographically normal
coronary arteries to severe multivessel disease (1). However,
when severe organic stenosis is present, spasm occurs at the
site of organic stenosis in 90% of cases (2). Therefore,
elimination of severe stenosis by percutaneous coronary
intervention (PCI) may be a useful treatment modality
(3,4). Case reports have suggested that patients with med-
ically refractory CSA and severe stenosis can be treated
successfully with intracoronary stenting and calcium antag-
onist administration (4–6). However, multivessel coronary
spasm occurs in many patients with CSA, especially in those
with angiographically normal or nearly normal coronary
arteries (7). The incidence of multivessel spasm in patients
with CSA and severe organic stenosis remains to be deter-
mined.
We hypothesized that if coronary spasm occurs only at a
site of severe organic stenosis, PCI may prevent spastic
coronary occlusion. To determine whether coronary spasm
occurs only at a site of severe organic stenosis or at different
sites, we performed spasm provocative testing with intra-
coronary acetylcholine (ACh) before PCI in patients with
CSA and a severe, obstructive lesion. We also performed
repeat provocative testing at a time when there was no
restenosis, to assess the inducibility of spasm in the absence
of restenosis after PCI.
METHODS
Patients. For this study, the criteria for CSA were: 1)
angina at rest, occurring predominantly from midnight to
early morning; 2) pain relieved spontaneously or after the
administration of sublingual nitroglycerin in 5 min; 3)
ST-segment changes 0.1 mV, documented during pain
and disappearing with relief of pain; 4) no subsequent
evidence of myocardial infarction; or the provocation of
these events with intracoronary ACh administration. Forty-
five consecutive patients with CSA and severe organic
stenosis (70% lumen narrowing) who underwent PCI at
Shibata Hospital between November 1995 and December
2000 comprised the study group of the present study (Table
1). All patients had rest angina, and 25 patients also had
effort angina occurring mainly in the early morning. Thirty-
nine (86.7%) of 45 patients were diagnosed as having variant
angina, with documented ST-segment elevation associated
with either spontaneous or provoked angina. Written,
informed consent was acquired from each patient before the
study, and ethical approval was obtained.
Coronary arteriography (CAG) and intracoronary injec-
tion of ACh. All vasodilator drugs, except nitroglycerin,
were discontinued at least 48 h before CAG, which was
performed using a percutaneous transfemoral approach.
Control CAG images in the left and right anterior oblique
projections were obtained. An electrode catheter was in-
serted into the right ventricular apex through the femoral
vein and connected to a temporary pacemaker, with the
pacing rate set at 40 to 50 beats/min.
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Acetylcholine chloride (Daiichi Seiyaku, Tokyo, Japan)
was dissolved in 0.9% saline, and incremental doses (50 and
100 g) of ACh were injected into the left coronary artery
over 20 s. The interval between each injection was 5 min.
Left CAG was performed when either ST-segment changes
or chest pain developed or 1.5 to 3 min after initiation of
each injection. Acetylcholine in incremental doses of 20 and
50 g was injected into the right coronary artery over 20 s,
and right CAG was performed in the same way. If the
induced coronary spasm did not resolve spontaneously
within 5 min after the injection of ACh or if hemodynamic
instability or intolerably severe symptoms occurred, isosor-
bide dinitrate (ISDN) (2.5 to 5 mg) was injected into the
coronary artery. Arterial blood pressure and the 12-lead
electrocardiogram (ECG) were continuously monitored
during the study and recorded for 5 min after initiation of
the intracoronary ACh injection. Coronary spasm was
defined as total or subtotal occlusion (with delayed filling of
the distal segment) associated with the onset of chest pain or
ischemic ST-segment changes on the ECG, or both. At
completion of the protocol, 2.5 to 5 mg of ISDN was
injected into both coronary arteries, and CAG was per-
formed in multiple projections.
The severity of coronary artery disease was assessed by the
number of vessels with significant disease (70% diameter
stenosis after intracoronary ISDN administration). The
significantly diseased segment was analyzed quantitatively,
using an edge-detection system (Digital Cardiac Imaging,
Phillips Medical System, Best, the Netherlands). A magni-
fication factor based on the known size of the angiographic
catheter was used for calibration.
Patients were medicated with calcium channel antago-
nists and antiplatelet agents immediately after completion of
CAG.
The PCI procedure. Percutaneous coronary intervention
was performed in the conventional manner through the
femoral approach. Before the procedure, an intravenous
bolus dose of 10,000 IU of heparin was injected, and 2.5 to
5 mg of ISDN was administered into the target coronary
artery. Isosorbide dinitrate was also administered intrave-
nously at a rate of 2.5 to 5.0 mg/h for 24 h. If balloon
angioplasty alone resulted in 30% residual stenosis by
visual estimation, we judged this as an optimal result and
finished the procedure. If optimal results were not obtained
with balloon angioplasty alone, coronary stenting was per-
formed to obtain adequate lumen diameter.
Quantitative CAG was performed before and immedi-
ately after PCI, and the minimal lumen diameter, reference
diameter and percent diameter stenosis were determined.
Acute occlusion (24 h after PCI) and subacute occlusion
(24 h after PCI) were defined as total or subtotal occlusion
of the target vessels.
All patients continued to receive adequate doses of
calcium channel antagonists and antiplatelet drugs after
PCI.
Follow-up CAG and provocative testing. Follow-up
CAG and spasm provocative testing were performed ap-
proximately six months after PCI, similar to the way at the
initial examination. If there was evidence of exercise-
induced myocardial ischemia (demonstrated by ECG
and/or myocardial scintigraphy) due to restenosis (defined
as 50% diameter stenosis), repeat PCI was performed.
Follow-up CAG and spasm provocative testing were per-
formed again approximately six months after the repeat
PCI. The last test, when restenosis was not present at the
site of PCI, was used to assess the inducibility of coronary
spasm after PCI.
RESULTS
Spasm provocation before PCI. Coronary spasm was
induced at the site of severe organic stenosis in 30 (66.7%)
of 45 patients (95% confidence interval [CI] 52.9% to
Abbreviations and Acronyms
ACh  acetylcholine
CAG  coronary arteriography
CI  confidence interval
CSA  coronary spastic angina
ECG  electrocardiogram
ISDN  isosorbide dinitrate
PCI  percutaneous coronary intervention
Table 1. Clinical and Angiographic Data on 45 Patients
Age (yrs) 65  8 (range 46 to 78)
Gender (n) Male (37)/female (8)
Risk factors, n (%)
Hypertension 25 (55.5%)
Hyperlipidemia (TC 220 mg/dl) 10 (22.2%)
Smoking 35 (77.8%)
DM 10 (22.2%)
No. of diseased vessels
One 42
Two 3
Dilated vessel
LAD 22
RCA 18
LCx 6
Reference diameter (mm) 2.9  0.4
Minimal lumen diameter (mm)
Before angioplasty 0.8  0.2
After angioplasty 2.7  0.5
Follow-up 2.1  0.5
Degree of stenosis (%)
Before angioplasty 74  5
After angioplasty 15  9
Follow-up 31  13
Stent type and no. (25 patients, 26 lesions)
Palmaz-Shatz 7
Wiktor 1
GFx 3
MultiLink 12
NIR 3
Data are presented as the mean value  SD or number (%) of patients.
DM diabetes mellitus; LAD  left anterior descending coronary artery; LCx 
left circumflex coronary artery; RCA  right coronary artery; TC  total cholesterol.
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80.5%) (Fig. 1A). Of these 30 patients, the induced spasm
was limited to the site of the severe organic stenosis in 18
patients, but it was also induced in another vessel in 12
patients. Coronary spasm was not induced at the site of
severe organic stenosis in 15 of 45 patients (Fig. 1B). Spasm
occurred at a site different from the severe stenosis in the
same vessel in 11 patients (proximal to the stenosis in 2
patients; distal in 9 patients) with (n  6) or without (n 
5) spasm induced in another vessel, and spasm was limited
to another vessel in 4 patients.
Results of PCI. Percutaneous coronary intervention was
successful in all patients (Table 1). Twenty patients were
treated with balloon angioplasty alone, and the remaining
25 patients were treated with intracoronary stenting. Cor-
onary spasm did not occur during the procedure, and neither
acute nor subacute occlusion was recognized in any patient.
Clinical follow-up. All patients took calcium channel an-
tagonists as prescribed. Anginal attacks, including both rest
and effort angina, were completely suppressed in all but one
patient during follow-up. This patient experienced recurrent
Figure 1. Flow chart of spasm provocative testing before percutaneous coronary intervention (PCI) and at follow-up in a group of 30 patients with spasm
superimposed on the severe organic stenosis before PCI (A) and in group of 15 patients without spasm superimposed on the severe organic stenosis before
PCI (B).
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episodes of angina with minimal effort in the early morning
and was found to have severe restenosis. The recurrent
angina resolved completely after the second PCI.
Follow-up CAG and spasm provocation. One patient
with multivessel coronary artery spasm before PCI refused
follow-up CAG, but had no scintigraphic evidence of
myocardial ischemia six months after PCI. Another patient
who had simultaneous left anterior descending and circum-
flex coronary artery spasm, as well as subsequent profound
hypotension during spasm provocation before PCI, refused
further provocative testing at follow-up. Five patients,
including one patient with symptomatic recurrence, showed
restenosis at the site of PCI and underwent a second PCI.
One patient from this group had a second restenosis and
underwent a third PCI.
Coronary artery spasm provocation with intracoronary
ACh was performed in 43 patients at 7  3 months after
the first provocative test, at a time when all patients were
free of restenosis. Although coronary spasm was never
induced at exactly the same site of the initial stenosis that
had been dilated (Fig. 1), spasm was induced at a site
different from the initial stenosis in the dilated vessel in 30
patients with (n  23) or without (n  7) spasm induced in
another vessel, and it was induced only in another vessel in
3 patients. Coronary spasm was not induced in any vessel in
10 patients (22.2%; 95% CI 10.1% to 34.3%).
Figure 1A shows the results of follow-up provocative
testing in 30 patients with spasm superimposed on the
severe organic stenosis before PCI. Coronary spasm was
induced at a site different from the initial stenosis in the
dilated vessel in 18 (60%) of 30 patients (95% CI 42.5% to
77.5%) with spasm superimposed on the severe organic
stenosis before PCI. Of the 18 patients with spasm initially
limited to severe organic stenosis without another vessel
spasm, spasm was not induced in any vessel in 9 patients and
was induced at a site different from the initial stenosis in the
dilated vessel in the remaining 9 patients. Of the 12 patients
with spasm induced both at the site of severe organic
stenosis and in another vessel before PCI, spasm was
induced at a site different from the initial stenosis in the
dilated vessel in 9 patients. Figure 1B shows the results of
follow-up provocative testing in 15 patients without spasm
superimposed on the severe organic stenosis before PCI.
Spasm was induced at a site different from the initial
stenosis in all patients of this group.
Coronary spasm was not induced in any vessel in 5 of 20
patients treated with balloon angioplasty alone (Fig. 2A) or
in 5 of 25 patients treated with coronary artery stenting (Fig.
2B). Although a mild coronary vasoconstrictor response was
recognized, coronary spasm was never induced at the site of
the initial stenosis that had been dilated by balloon angio-
plasty alone. Coronary vasoconstriction was completely
suppressed, and coronary spasm was never induced at the
site of the initial stenosis that had been dilated by coronary
artery stenting. However, coronary spasm was induced at
the edge of the implanted stent in 7 (28%) of 25 patients
(95% CI 10.4% to 45.6%) (Fig. 3). Spasm was induced at
the distal edge in four patients and at the distal and the
proximal edges in three patients.
Multivessel spasm occurred on one or both spasm pro-
vocative tests in 28 (62.2%) of 45 patients (95% CI 48.0% to
76.4%) with CSA and severe stenosis.
DISCUSSION
Although coronary spasm is most commonly induced at the
site of severe organic stenosis before PCI and never induced
at the dilated site on the follow-up test, when there is no
restenosis after PCI, coronary spasm is induced at a site
different from the initial stenosis in the dilated vessel and/or
in another vessel in most patients at follow-up. Multivessel
spasm occurs frequently, even in patients with CSA and
severe stenosis.
Spasm provocation with intracoronary ACh in patients
with CSA and significant stenosis. MacAlpin (2) reported
that coronary spasm occurs at a site of preexisting organic
stenosis in almost 90% of patients with CSA. Other reports
have also shown that most coronary spasms are superim-
posed on fixed, severe atherosclerotic narrowing (8,9).
These studies used intravenous ergonovine to provoke
coronary spasm (8,9). Once the spasm was induced in one
coronary artery, the test was terminated, because nitroglyc-
erin was administered to relieve the coronary spasm (10,11).
Thus, the response of the other coronary artery to higher
doses of ergonovine could not be examined. In patients with
CSA and severe organic stenosis, coronary spasm was
induced at the site of severe stenosis, using a relatively low
dose of ergonovine (3). Therefore, multivessel coronary
spasm was rarely recognized during provocative testing,
using ergonovine maleate in patients with CSA and severe,
obstructive lesions.
Intracoronary injections of ACh have been used for
provocation of coronary spasm (7,12,13). The sensitivity
and reliability of ACh are as high as those of ergonovine
(13). The action of ACh is remarkably short, and the spasm
usually resolves spontaneously within 2 to 3 min in most
patients, without administration of nitroglycerin. Thus, it is
possible to examine the effect of ACh on the contralateral
artery (7,13). By this method, multivessel coronary artery
spasm can be recognized in many patients with CSA,
especially in those with angiographically normal or nearly
normal coronary arteries (7). However, no systematic stud-
ies have reported the incidence of multivessel coronary
spasm in patients with CSA and severe organic stenosis. We
found that spasm was most commonly induced at the site of
severe organic stenosis, but more than half of the patients
had multivessel coronary spasm, even in the presence of
severe organic stenosis. Multivessel coronary spasm is not a
rare phenomenon; it can occur or be induced in many
patients with CSA who have coexistent severe coronary
stenosis.
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Provocation of coronary spasm after coronary angioplasty
or stenting. The results of PCI for patients with CSA and
severe organic stenosis have been shown to be less satisfac-
tory than those for patients with fixed organic stenosis
(3,8,14). Patients in whom calcium channel antagonists
were discontinued soon after PCI have an exceedingly high
rate of restenosis, and continued spasm is associated with
restenosis (3,8). Furthermore, patients with restenosis have
Figure 2. Flow chart of spasm provocative testing before percutaneous coronary intervention and at follow-up in a group of 20 patients treated with balloon
angioplasty alone (A) and in a group of 25 patients treated with intracoronary stenting (B). *Twenty patients with spasm induced at a site different from
the initial stenosis in the dilated vessel on follow-up provocation, including seven patients with spasm induced at the edge of the implanted stent.
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coronary spasm superimposed on restenosis (8,9). Bertrand
et al. (8) have shown that coronary spasm can be induced at
the restenosis site in 81.5% of patients with CSA.
We performed a spasm provocative test at a time when
follow-up angiography showed no evidence of restenosis, to
determine whether dilation of severe stenosis and no sub-
sequent restenosis prevent spastic occlusion of the dilated
vessel. The results revealed that not only were the vasocon-
strictor response and spasm mechanically suppressed at the
site of the initial stenosis that had been dilated by intra-
coronary stenting, but also that coronary spasm was sup-
pressed at the site of the initial stenosis that had been
dilated by balloon angioplasty alone. However, only 10
(22.2%) of 45 patients had no evidence of coronary spasm at
follow-up provocation, even in the absence of restenosis.
Spasm was induced at the different site in the dilated vessel
in 70% of patients and in another vessel in 60% of patients.
Of the 30 patients with spasm superimposed on the
severe organic stenosis before PCI, 18 patients (60%)
showed spasm induced at a site distal to the dilated lesion.
The possibility of multifocal spasm in the same vessel,
which could not be recognized when the spasm occurred at
a proximal stenosis, should be considered even when the
spasm was limited to severe organic stenosis before PCI.
Interestingly, spasm occurred at the edge of the implanted
stent in 28% of patients treated with intracoronary stenting.
A diffuse disorder in coronary artery vasomotility is recog-
nized in Japanese patients with CSA (15,16). Coronary
stents may trigger the vasospasticity of the vessel at the edge
of the stent when a diffuse disorder of coronary artery
vasomotility is present.
Heterogeneity of coronary artery spasm. Coronary spastic
angina with coexistent organic stenosis probably includes
two apparently distinct types. One type is a “localized”
vasomotility disorder, including typical Prinzmetal’s variant
angina, which results from a temporary occlusion of a large
diseased artery due to normal increases in vascular wall tone
(as suggested by Prinzmetal) or due to abnormally increased
vasospasticity in the severely stenotic lesion (17–20). This
type of CSA may be common in American and European
Figure 3. Initial (A, B) and follow-up (C, D) angiograms of the left coronary artery obtained in the right anterior oblique projection. (A) Intracoronary
injection of 50 g acetylcholine (ACh) induced occlusive spasm at the site of severe stenosis (arrow). (B) After intracoronary injection of isosorbide dinitrate
(ISDN), severe organic stenosis was present at the proximal left anterior descending coronary artery (arrow). (C) Intracoronary injection of 50 g ACh
induced subocclusive spasm at the edge of the stent (arrowhead) in the left anterior descending coronary artery, as well as occlusive spasm in the proximal
left circumflex coronary artery; the stented portion at the site of the initial stenosis (arrow) was free of vasoconstriction. (D) After intracoronary injection
of ISDN, there was no restenosis at the initial stenosis (arrow) that had been dilated by intracoronary stenting.
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patients, most of whom have severe organic stenosis, in
contrast to most Japanese patients, who have nearly normal
coronary arteries (1,2,7,17–19). Bertrand et al. (9) showed
that coronary spasm was induced in only 16 (26.6%) of 60
patients who were free of restenosis after PCI. Corcos et al.
(3) also demonstrated that coronary spasm was not induced
in most patients with CSA, in the absence of restenosis
after PCI. These results differ from the present findings
that spasm was not inducible in only 22.2% of patients who
were free of restenosis after PCI. Most of the patients
included in these studies appear to have typical Prinzmetal’s
variant angina, with spasm occurring only at the site of
severe stenosis. Therefore, PCI would probably be more
effective in treating CSA with severe organic stenosis in
American and European patients, as compared with Japa-
nese patients.
The other type is coronary spasm in which a diffuse, not
localized, disorder in vasomotility is involved, even in the
presence of organic severe stenosis. This type is commonly
found in Japanese patients with CSA and normal or nearly
normal coronary arteries (15,16), and most of these patients
show multivessel spasm (7). Our study revealed that most
coronary spasms were not the “localized” type, even in the
presence of severe atherosclerotic coronary stenosis in Jap-
anese patients. This type of CSA is never cured by elimi-
nation of the coexistent severe organic stenosis using PCI.
Study limitations. Spasm provocation with intracoronary
ACh was highly sensitive, but failed to induce coronary
spasm in some patients with very low disease activity (13).
In the present study, spasm induced in nondilated vessels
before PCI became negative at follow-up in four patients.
These findings may be due to markedly reduced disease
activity, because coronary spasm was completely suppressed
by calcium channel antagonists during the follow-up period
after PCI. A time-related decrease in inducibility of spasm
has been recognized, even after the interruption of calcium
channel antagonists (21). Therefore, spasm not induced at
follow-up does not necessarily indicate a cure of CSA. The
provocation rate of coronary spasm would have been under-
estimated at the time of follow-up.
Clinical implications. Coronary spasm was never induced
at exactly the same site of the initial severe stenosis that had
been dilated in the absence of subsequent restenosis, but it
did occur at a different site in the dilated vessel and/or in
another vessel after elimination of the organic stenosis in
most patients. Calcium channel antagonists should be
continued in most patients who underwent PCI for the
treatment of CSA with severe stenosis, even in the absence
of subsequent restenosis. Discontinuation of calcium chan-
nel antagonists should be limited to patients who have
localized spasm superimposed on severe organic stenosis
before PCI, with no subsequent restenosis after PCI and no
inducible spasm at follow-up.
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